scholarly journals Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

2019 ◽  
Author(s):  
Wenhuan Li ◽  
Ji-Yu Zhang ◽  
Wen-Hui Liu ◽  
Xian-Xian Chen
Keyword(s):  
Gastric Cancer ◽  
Progression Free Survival ◽  
Treatment Method ◽  
Clinicopathological Characteristics ◽  
Free Survival ◽  
Initial Degree ◽  
Patient Prognosis ◽  
Gastric Cancer Patients ◽  
The Relationship

Abstract Background: Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC. Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent GCs and metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of chemotherapy-related reduction in haemoglobin was further analysed. Results: Our results revealed that patients with HBini level ≤ 80 g/L had a trend toward a shortened median OS and PFS (p=0.009 and p=0.049, respectively). Interestingly, we also found that HBdec ≥30 g/L was associated with a significantly shortened median OS and PFS (p=0.039 and p=0.001, respectively). Multivariate analysis showed that HBini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HBdec ≥30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles. Conclusion: Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥ 30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, paclitaxel should not be recommended for treating severely anaemic GC patients.

scholarly journals Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

2020 ◽  
Author(s):  
Wenhuan Li ◽  
Ji-Yu Zhang ◽  
Wen-Hui Liu ◽  
Xian-Xian Chen
Keyword(s):  
Gastric Cancer ◽  
Progression Free Survival ◽  
Treatment Method ◽  
Clinicopathological Characteristics ◽  
Free Survival ◽  
Initial Degree ◽  
Patient Prognosis ◽  
Gastric Cancer Patients ◽  
The Relationship

Abstract Background ：Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC. Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent or metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of cancer related reduction in haemoglobin was further analysed. Results : Our results revealed that patients with HB ini level ≤ 80 g/L had a trend toward a shortened median OS and PFS ( p =0.009 and p =0.049, respectively). Interestingly, we also found that HB dec ≥30 g/L was associated with a significantly shortened median OS and PFS ( p =0.039 and p =0.001, respectively). Multivariate analysis showed that HB ini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HB dec ≥30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles. Conclusion : Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥ 30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, platinum should not be recommended for treating severely anaemic GC patients.

scholarly journals Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

2020 ◽  
Author(s):  
Wenhuan Li ◽  
Ji-Yu Zhang ◽  
Wen-Hui Liu ◽  
Xian-Xian Chen
Keyword(s):  
Gastric Cancer ◽  
Progression Free Survival ◽  
Treatment Method ◽  
Clinicopathological Characteristics ◽  
Free Survival ◽  
Initial Degree ◽  
Patient Prognosis ◽  
Gastric Cancer Patients ◽  
The Relationship

Abstract Background：Anaemia is highly prevalent in gastric cancer (GC) patients. The role of initial haemoglobin levels in predicting the prognosis of GC patients treated by chemotherapy has not been well determined. Our present study aims to evaluate the relationship between the degree of anaemia and the overall survival (OS) and progression-free survival (PFS) of patients with GC.Methods: Our retrospective study enrolled 598 patients who were treated with chemotherapy when the recurrent or metastatic GCs were unsuitable for surgical resection. Univariate and multivariate analyses were performed to identify risk factors that had the potential to affect patient prognosis. Additionally, the relationship between clinicopathological characteristics, including treatment method, and degree of cancer-related reduction in haemoglobin was further analysed.Results: Our results revealed that patients with HBini level ≤ 80 g/L had a trend toward a shortened median OS and PFS (p=0.009 and p=0.049, respectively). Interestingly, we also found that HBdec ≥30 g/L was associated with a significantly shortened median OS and PFS (p=0.039 and p=0.001, respectively). Multivariate analysis showed that HBini levels ≤80 g/L could be used as an independent prognostic factor for recurrent and metastatic GC. More importantly, HBdec ≥30 g/L and treatment response were also significantly associated with OS and PFS. Furthermore, the degree of haemoglobin decrease was associated with chemotherapy including platinum and the number of chemotherapy cycles.Conclusion: Our study concludes that the initial degree of anaemia and a decrease in haemoglobin of ≥ 30 g/L can serve as biomarkers to predict prognosis in recurrent or metastatic GC patients, while chemotherapy treatment rather than red blood cell (RBC) transfusion can improve their prognosis. Additionally, platinum should not be recommended for treating severely anaemic GC patients.

scholarly journals Role of initial anemia degree and treatment model on the prognosis of recurrent gastric cancer

2019 ◽  
Author(s):  
Wenhuan Li ◽  
Ji-Yu Zhang ◽  
Wen-Hui Liu ◽  
Xian-Xian Chen
Keyword(s):  
Gastric Cancer ◽  
Treatment Response ◽  
Progression Free Survival ◽  
Radical Resection ◽  
Clinicopathological Characteristics ◽  
Prognosis Prediction ◽  
Recurrent Gastric Cancer ◽  
The Relationship ◽  
Rbc Transfusion

Abstract Background:Anemia is highly prevalent in recurrent gastric cancer patients. The role of initial hemoglobin levels on prognosis prediction of in recurrent gastric cancer has not been well determined. Our present study aims to evaluate the relationship of the anemia degree and the Overall survival (OS) and Progression-free survival (PFS) of the patients with recurrent gastric cancer. Methods:Our study enrolled 598 patients who were treated with chemotherapy when the recurrent gastric cancer were diagnosed after radical resection. Univariate and multivariate analyses were preformed to identify risk factors which has the potential to affect the patient prognosis. Besides, the relationship between clinicopathological characteristics including treatment styles and chemotherapy-related hemoglobin reduction degree were further analyzed. Results: Our results revealed that patients with HBini level ≤ 80 g/L had also a trend of shortened median OS and PFS (p=0.009 and p=0.049, respectively). Interesting, we also found that, HBdec ≥30 g/L was associated with significantly shortened median OS and PFS (p=0.039 and p=0.001, respectively). Multivariate analysis showed that HBini level ≤80 g/L could be used as independent prognostic factors for recurrent gastric cancer. More important, HBdec ≥30 g/L and treatment response also were significantly associated with OS and PFS. Besides, the degree of hemoglobin decrease was associated with chemotherapy include platinum, the number of chemotherapy cycles, treatment response rather than red blood cell (RBC) transfusion. Conclusion: Our study concludes that initially degree of anemia can serve as a biomarker of recurrent GC patients prognosis prediction, while chemotherapy treatment rather than RBC transfusion can improve those patient’s OS and PFS. Besides, paclitaxel should not be recommended to treat the recurrent GC patients.

scholarly journals KLHL5 Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Gastric Cancer

2020 ◽  
Vol 7 ◽  
Author(s):  
Qiulin Wu ◽  
Guobing Yin ◽  
Jinwei Lei ◽  
Jiao Tian ◽  
Ailin Lan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Outcomes ◽  
Immune Cell ◽  
Progression Free Survival ◽  
Differentially Expressed ◽  
Free Survival ◽  
Kaplan Meier ◽  
Patient Prognosis ◽  
The Relationship ◽  
Kaplan Meier Plotter

Background: KLHL5 (Kelch Like Family Member 5) is differentially expressed in gastric cancer, but its correlation with prognosis and functioning mechanism in gastric cancer remain unclear.Methods: The Oncomine database and TIMER were employed to appraise the KLHL5 expression in a variety of cancers. The correlation between KLHL5 expression and patient prognosis was extracted from the Kaplan–Meier plotter, GEPIA, and PrognoScan database. Then the relationship between KLHL5 expression and inflammatory infiltrate profiles was inquired by TIMER. Finally, GEPIA and TIMER were explored for the correlative significance between KLHL5 expression and immune cell–related marker sets.Results: KLHL5 was found to be differentially expressed and correlated with clinical outcomes in several types of cancers in the TCGA database. Especially, KLHL5 mRNA expression was upregulated and correlated with poorer overall survival and progression-free survival in gastric cancer. Moreover, elevated KLHL5 expression was significantly related with patient node stage, infiltration level, and expression of multiple immune marker sets.Conclusions: These results implicate that KLHL5 expression is closely linked with patient clinical outcomes and the microenvironmental infiltration level in different neoplasms. This indicates that KLHL5 is a modulator in infiltrate recruitment, shaping the landscape of immune cell infiltration. Thus, it represents an eligible prognostic predictor for gastric malignancy.

scholarly journals Reduction in Peripheral CD19+CD24hCD27+ B Cell Frequency Predicts Favourable Clinical Course in XELOX-Treated Patients with Advanced Gastric Cancer

2017 ◽  
Vol 41 (5) ◽  
pp. 2045-2052 ◽  
Author(s):  
Wei Li ◽  
Dongli Song ◽  
Hong Li ◽  
Li Liang ◽  
Naiqing Zhao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Progression ◽  
Clinical Course ◽  
Progression Free Survival ◽  
Effective Rate ◽  
Median Percentage ◽  
Free Survival ◽  
Gastric Cancer Patients ◽  
The Relationship

Background: Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating the immune response to tumours. Our previous study indicated that a small percentage of peripheral CD19+CD24hCD27+ Breg cells slowed gastric cancer progression in XELOX-treated patients. Here, we further investigated the relationship between dynamic changes in circulating Breg cells and the clinical course in XELOX-treated gastric cancer patients. Methods: A total of 52 patients with advanced gastric cancer were enrolled in this study. The frequencies of CD19+CD24hCD27+ cells in peripheral blood were tested before (as a baseline) and 9 weeks after administration of oxaliplatin and capecitabine (XELOX). The primary endpoint of the study was progression-free survival time (PFS) of the patients. The overall survival (OS) and adverse events of chemotherapy were also recorded. Results: The median PFS of patients was 6 months (95% CI, 5.27-6.73) with effective rate of 46.2%. The percentage of CD19+CD24hCD27+ cells in lymphocytes ranged from 0.007% to 1.94%, with a median value of 0.45%. The median percentage of CD19+CD24hCD27+ lymphocytes was 0.59% (0.01%-6.02%) 9 weeks after treatment. There were no significant differences for this index. However, the patients with decreased Breg frequencies after XELOX treatment had a longer PFS time (7.0 months vs. 5.0 months, p=0.01) than those with increased Breg frequencies. Conclusion: Patients with downtrend of CD19+CD24hCD27+ B lymphocytes during early stages of chemotherapy relative to their initial values had longer PFS times, and this could be used to predict the efficacy of chemotherapy and help physicians adjust treatments accordingly.

scholarly journals MNG-03 PD-L1 EXPRESSION, PATIENT PROGNOSIS AND INITIAL WHO GRADE IN GRADE II/III MENINGIOMA

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii36-ii36
Author(s):  
Dai Kamamoto ◽  
Hikaru Sasaki ◽  
Ryota Sasao ◽  
Takumi Fujiyama ◽  
Kazunari Yoshida
Keyword(s):  
Radiation Therapy ◽  
Progression Free Survival ◽  
Who Grade ◽  
Free Survival ◽  
Specific Data ◽  
Tumor Immune Evasion ◽  
Significant Difference ◽  
Grade Ii ◽  
Patient Prognosis ◽  
The Relationship

Abstract The optimal treatment for grade II/III meningioma is operation with or without radiation therapy. However, their natural course is sometimes aggressive with high recurrent rate. There is no effective treatment other than operation and radiation therapy, therefore, a new therapeutic strategy for grade II/III meningioma is urgently required.PD-1 and PD-L1 play important roles as immune-checkpoint mediators within tumor microenvironment and the antibodies to these molecules are now approved for the treatment of various kinds of cancers. In Japan, anti-PD-1 antibody and anti-CTLA-4 antibody are approved for unresectable melanoma or advanced / recurrent non-small cell lung cancer and their high effectiveness has been reported. We investigated the expression of PD-L1 (clone:28-8) in 51 cases of grade II/III meningioma by immunohistochemistry and analyzed the relationship between the expression with overall survival, progression free survival and initial WHO grade. For now, we have evaluated 25 cases of PD-L1 immunohistochemistry and PD-L1 showed positivity in 15 cases. There is no correlation observed between PD-L1 expression and patients’ prognosis. Although it does not reach a significant difference, the WHO grade at the time of initial operation tends to be high in those with high PD-L1 staining rate.Similar studies that were previously reported did not use antibodies targeting clone 28-8, which was used as a companion diagnosis for nivolumab administration, but “Correlation between PD-L1 expression and WHO grade”, or “PD-L1 expression is an independent prognostic factor” have been reported. In our investigation, which was using antibodies for companion diagnosis, PD-L1 was positive in more than half of Grade II / III meningiomas and it also related to WHO grade. These results suggest the possibility that tumor immune evasion mechanisms are also working in meningiomas. At the conference, we will report it with the specific data from all cases with a literature review.

scholarly journals Study on the Relationship between Expression of LGR5 and Clinicopathological Characteristics in Gastric Cancer Patients

Health ◽  
2018 ◽  
Vol 10 (01) ◽  
pp. 159-169
Author(s):  
Xiulian Xu ◽  
Qijun Lv ◽  
Ping Xie ◽  
Shoujiang Wei ◽  
Chongshu Wang
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinicopathological Characteristics ◽  
Gastric Cancer Patients ◽  
The Relationship

Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 185-185
Author(s):  
Naoki Fukuda ◽  
Daisuke Takahari ◽  
Hiroki Osumi ◽  
Tomohiro Matsushima ◽  
Izuma Nakayama ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Predictive Factors ◽  
Performance Status ◽  
Objective Response ◽  
Progression Free Survival ◽  
Independent Factor ◽  
Ecog Performance Status ◽  
Free Survival ◽  
Gastric Cancer Patients

185 Background: Ramucirumab (RAM) is a novel anti-VEGF antibody approved in 2015 in Japan. Predictive factors for RAM in combination with paclitaxel (PTX) remain largely unknown. Methods: We reviewed 77 consecutive advanced gastric cancer patients who were treated with RAM plus PTX between June 2015 and June 2016 in our institution. We evaluated treatment outcome and analyzed potential predictive factors by univariate and multivariate analyses. Results: Median age was 67 years (range 35-83) and 51 % of the patients were male. The ECOG performance status (PS) was ≥ 2 in 8 patients. 89% (69/77) patients were treated as second line chemotherapy. Objective response rate (ORR) in patients who have measurable disease was 52 % (17/33). Median progression free survival (PFS) and overall survival (OS) and was 6.0 months (95% confidence interval [CI] = 4.3-7.1) and 10.4 months (95% CI 6.8-13.6), respectively. The most frequent adverse events were peripheral neuropathy (44%), G3 ≥ neutropenia (34%), hypertension (32%) and bleeding (27%). At multivariate analysis, hypertension was independent factor for OS (Hazard ratio [HR] = 0.35, 95% CI = 0.14-0.90, P = 0.03). Also, bleeding (HR = 0.23, 95% CI = 0.09-0.55, P = 0.001) was independent factor for PFS and hypertension (HR = 0.47, 95% CI = 0.22-1.02, P = 0.06) had trend toward to show better PFS. Conclusions: RAM plus PTX showed promising efficacy for advanced gastric cancer. RAM related toxicities such as hypertension and bleeding/hemorrhage were independent factors for better outcome. Further investigation is warranted to verify our analysis.

scholarly journals Cholinesterase is Associated With Prognosis and Response to Chemotherapy in Advanced Gastric Cancer

2021 ◽  
Vol 27 ◽  
Author(s):  
Yanzhi Bi ◽  
Junling Zhang ◽  
Dongxiang Zeng ◽  
Lili Chen ◽  
Wei Ye ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Serum Level ◽  
Objective Response ◽  
Multivariate Logistic Regression Analysis ◽  
Progression Free Survival ◽  
Post Treatment ◽  
Clinical Value ◽  
Free Survival ◽  
Response To Chemotherapy ◽  
The Relationship

Background: Cholinesterase (CHE) is a routine serum biomarker in gastric cancer (GC). However, little research has been done on its clinical value in advanced GC. In addition, it is not clear whether it can be used as biomarker for the response and prognosis of advanced GC patients.Methods: Between Jan. 2013 and Dec. 2016, a total of 150 patients with advanced GC treated with first-line chemotherapy were admitted to Changzhou Tumor Hospital Affiliated to Soochow University. We retrospectively identified serum CHE level on the day before chemotherapy and at the end of chemotherapy and abstracted clinicopathologic features and treatment outcomes. Univariate and multivariate survival analyses were performed to assess the relationship between serum CHE levels and progression-free survival (PFS) and overall survival (OS).Results: A total of 150 advanced GC patients were included and divided into serum level ≥5,000 IU/L and serum level <5,000 IU/L. CHE level lower than 5,000 IU/L was associated with poorer PFS (HR, 1.60; 95% CI, 1.141–2.243; p = 0.006), poorer OS (HR, 1.76; 95% CI, 1.228–2.515; p = 0.002) and trend of poorer response (HR, 0.56; 95% CI, 0.272–1.129; p = 0.104). In univariate and multivariate logistic regression analysis, only liver metastasis and PS score were significantly associated with objective response (p < 0.05). The medium PFS was 8.0 months in patients with post-treatment CHE increased vs. 3.8 months in patients with CHE decreased after chemotherapy (HR, 1.82; 95% CI 1.28–2.57; p = 0.0002). The medium OS was 13.1 months in patients with increased post-treatment CHE vs. 8.1 months in patients with decreased post-treatment CHE (HR, 1.87; 95% CI 1.29–2.71; p = 0.0002).Conclusion: Advanced GC with CHE levels below 5,000 IU/L was significantly associated with poor PFS and OS. The results suggested that CHE analysis before chemotherapy was a promising prognostic marker for advanced GC.

Sign in / Sign up

Export Citation Format

Share Document